Media Release 7.11.11 from Porton Group - 3M Forced to Pay for Breach of Obligations over MRSA - High Court - Investment fund manager Porton Group and the Ministry of Defence subsidiary Ploughshare Innovations* today won a court battle with 3M over the multi-national company's failure to promote a test for the "superbug" MRSA. The High Court in London found 3M was "in material breach of its obligation"...

Appearances and analysis by former MRSA Support chairman Tony Field, who is calling for further transparency regarding 3M’s decision to leave BacLite on the shelve and questioning why 3M’s chairman, Mr. George Buckley, is being knighted at a time when the UK government is involved in a lawsuit against 3M. BacLite was a proven, major breakthrough in MRSA detection that held the promise of saving thousands of lives and millions of dollars. It was...

At a press conference in Minneapolis, next door to "twin city" St. Paul, Minnesota, home of 3M's international headquarters, attorneys for Porton, Lanny J. Davis of Washington, D.C. and Robert Hopper of Minneapolis, cited a secret report by an 11-member internal 3M technical committee that confirmed 3M testers had made fundamental errors that led to unacceptable 50% reliability results.

BacLite's efficacy and reliability was not only confirmed by EU regulators after rigorous clinical trials produced verifiable results in the 95% range. Those findings were corroborated by multiple peer-reviewed scientific studies. Peer-reviewed works verified that BacLite fills the niche between more expensive molecular/DNA product and less expensive, more time-consuming - and sometimes less reliable - culture methods.